Blog
Medical devices

5 Trends Shaping the Future of Medical Device Clinical Trials

The medical device industry is evolving rapidly, driven by digital innovation, increasingly complex regulatory requirements, and increasing demand for real-world data. Yet many CROs continue to rely on outdated protocols built for pharmaceutical trials, not today’s intricate device studies.

The potential consequences? Challenges in obtaining regulatory approval, additional research to collect more data, delayed timelines, and increased costs.

To avoid these pitfalls, CROs must stay up-to-date with medical device industry trends, including: 

1. The Shift Toward Digital and Software-Based Devices

From AI-powered diagnostics to Bluetooth-enabled sensors, connected and software-driven devices are now at the center of medical devices. But these technologies bring unique challenges:

  • Validation for software updates and algorithms
  • Ongoing performance monitoring
  • Data privacy and interoperability considerations
  • Usability testing as part of regulatory submissions

Many CROs lack the infrastructure or experience to support iterative development cycles or software-specific endpoints. Without deep expertise in digital health, they risk overlooking critical elements, such as human factors testing or real-time data capture.

How to Stay Ahead:
CROs must evolve into partners who understand the technology development lifecycle and the regulatory nuances associated with software as a medical device (SaMD).

2. Usability and Workflow Integration

Today’s medical device sponsors must prove more than just safety and efficacy—they need to demonstrate ease of use, workflow compatibility, and the feasibility of training. If integrating a new technology into clinical practice disrupts day-to-day operations or requires steep learning curves, adoption can stall regardless of how promising the data may be. 

Traditional clinical trial designs—which require participants to visit physical sites for study activities—often fall short in capturing how treatments are actually used in real-world settings. As a result, CROs may treat onboarding, training validation, and clinician or patient usability as afterthoughts rather than essential outcomes that shape the success of a trial.

How to Stay Ahead:
CROs need to design trials that reflect real-world use. This means capturing feedback from users, integrating training support, and generating operational data that supports both approval and commercial success.

3. A Shift Toward Leaner, Faster, More Iterative Trials

Medical device companies, especially startups, are pushing for faster, more agile clinical programs. Device trials often require a broader mix of data types, covering performance, usability, human factors, and real-world integration. 

In addition, these trials are often plagued with the overly complex protocols seen in drug trials, capturing extraneous data and limiting participation with rigid eligibility criteria. This results in recruitment bottlenecks that ultimately slow the pace of innovation.

How to Stay Ahead:
To ensure more efficient device studies, your protocol should incorporate the following elements from the outset:

  • A fit-for-purpose design: Right-sized studies built around the device’s intended use and risk profile.
  • Usability and human factors testing: Integrated early to support labeling and market adoption.
  • Methods to streamline data capture: Prioritized endpoints that reflect regulatory needs without overcomplication.
  • Flexible eligibility criteria: Designed to match real-world users and usage settings.

4. Operational Excellence As a Competitive Advantage

From custom packaging and calibration to onsite setup and post-study returns, logistics can make or break a device trial. Medical devices may require special handling, multi-part kits, or specialized storage conditions. For many devices, site staff need hands-on demonstrations, clear handling instructions, and ongoing tech support to ensure proper use. 

Missteps in setup or training can delay enrollment, frustrate sites, and ultimately compromise data quality. That’s why device companies need a partner that understands these operational realities—not a CRO bound by the traditional pharma-first mindset.


How to Stay Ahead:
Device-savvy CROs plan logistics from day one. This includes utilizing site readiness assessments, patient-friendly packaging, comprehensive training workflows, and tech support as needed.

5. The Power of Decentralized and Hybrid Trials

Medical devices, especially wearables, offer unique opportunities to leverage decentralized or hybrid study models. These settings not only enhance evidence generation through assessing a product’s performance in real-world environments, but they lend way to more patient-centric research. Yet many CROs lack the infrastructure and digital tools to operate decentralized workflows effectively.

How to Stay Ahead:
Embrace tech-forward solutions for virtual trial execution, including:

  • ePRO/eCoA tools: For seamless, real-time patient-reported data collection.
  • Telemedicine capabilities: To enable virtual visits and remote check-ins.
  • Remote monitoring: To track device usage, compliance, and patient safety in real-world environments.
  • Device-specific logistics support: Including setup, storage, training, and retrieval tailored to the trial design.

CROs Must Improve Standards for Medical Device Research

As the medical device landscape continues to advance, traditional clinical trial approaches are no longer sufficient. Sponsors need partners who understand the nuances of, usability, iterative development, and operational complexity. From wearable sensors and smart dosing technologies to neurostimulation interventions and implantables, today’s devices require trials that are lean, flexible, and grounded in real-world use.

CROs that continue to rely on pharma-centric models risk falling behind—missing key insights, delaying regulatory approvals, and increasing costs. To stay competitive and support innovation, trial design must evolve alongside the technologies it seeks to evaluate.

Don’t Miss Our Webinar

Our live webinar, “What CROs Get Wrong About Medical Device Trials,” where industry leaders from Lindus Health, Glucotrack, and Motif Neurotech  explore why device trials require a fundamentally different approach than drug trials, is now available to watch on demand. You’ll learn how an integrated, expert-led team across clinical design, regulatory strategy, operations, and more can streamline development, accelerate approval, and improve market success.

Click here to watch on demand

This is some text inside of a div block.
This is some text inside of a div block.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Continue reading

More from Lindus

Lindus BG Image
11 Mar 2026
Blog

Achieving FDA-Grade Data Quality in Large-Scale Liquid Biopsy Screening Trials

"The data pipeline, from medical record retrieval to structured EDC output, has to be designed for regulatory scrutiny from the start. Retrofitting data quality into an operational model that wasn't built for it creates avoidable risk at exactly the wrong stage of a program."

Lindus BG Image
26 Feb 2026
Blog

Maintaining Complete Long-Term Follow-Up Data in Large-Scale Oncology Screening Trials

Every cancer case in a large screening trial must be fully documented, with complete diagnostic, staging, treatment, and outcome data. Losing even a small number of cases to incomplete follow-up can undermine the statistical power the entire study was designed to achieve. The operational model has to be built around preventing that from the start.

Lindus BG Image
17 Feb 2026
Blog

Scaling Liquid Biopsy Trial Enrollment Through Decentralized and Hybrid Models

"Clinical trials for diagnostics are increasingly time-consuming and expensive, given the large volumes of patients required. Identification and proper enrollment at accredited sites alongside novel methods of reaching patients remotely are promising developments for speeding and focusing efforts."

Lindus BG Image
20 Jan 2026
Blog

Why the FDA's Bayesian Draft Guidance Matters for Clinical Development

Last week, the FDA published draft guidance designed to facilitate the use of Bayesian methodologies in clinical trials of drugs and biologics. It is a welcome step toward faster, more practical clinical development that puts patients first, especially those for whom a clinical trial is often their best hope.